A gut-specific pairing that combines a mucosal "repair" peptide with a targeted anti-inflammatory tripeptide, marketed for leaky gut, IBS, and IBD/colitis-adjacent symptoms rather than the tendon/ligament use case BPC-157 is better known for.
Why it matters
BPC-157 is theorized to help rebuild the damaged gut lining, while KPV — a peptide fragment reported to be anti-inflammatory — is meant to calm the inflammation driving that damage.
The published per-compound doses, timing, cycle length, the mechanism sources give for why it's combined, and the harm-reduction notes — the parts that took the most research to get right — are part of membership.
